After blood collection, sera were separated by centrifugation at 3000 × g for 10 min and stored at −80°C until use. Anti-NC-Ab and anti-RBD-Ab were quantified with electrochemiluminescence immunoassays, Elecsys® Anti-SARS-CoV-2 (S300) RUO and Elecsys® Anti-SARS-CoV-2 S (S300) RUO (Roche Diagnostics, IN, USA), respectively. These assays were performed with a fully automated Cobas 8000 Analyzer Series Module e801 (Roche Diagnostics). Results are expressed in terms of a cutoff index (COI) or a cutoff concentration. The presence of anti-NC-Ab was positive when the detection value was ≥1.0 COI, and the presence of anti-RBD-Ab was positive when the detection value was ≥0.8 U/mL. The ability of NAbs to inhibit SARS-CoV-2 binding to its target was quantified, in duplicate, with an enzyme-linked immunosorbent assay (ELISA)-based SARS-CoV-2 Surrogate Virus neutralization Test (sVNT) Kit (GenScript, Jiangsu, China) [12 (link)]. The cutoff level (lower limit of quantification) for the positive detection of NAbs was set at 30% inhibition, according to manufacturer instructions.
Cobas 8000 analyzer series module e801
Manufactured by Roche
The Cobas 8000 analyzer series module e801 is a laboratory equipment used for in vitro diagnostic testing. It is designed to perform immunochemistry and clinical chemistry analyses. The e801 module is part of the Cobas 8000 analyzer series, which is a modular system for high-throughput clinical laboratory testing.
Automatically generated - may contain errors
Lab products found in correlation
Elecsys anti sars cov 2 s300 ruo, by Roche (1 mentions)
Sars cov 2 surrogate virus neutralization test kit, by GenScript (1 mentions)
Jca bm8060, by JEOL (1 mentions)
L type wako glu2, by Fujifilm (1 mentions)
Labospect008α, by Hitachi (1 mentions)
Jca bm9130, by JEOL (1 mentions)
Acquity uplc system, by Waters Corporation (1 mentions)
Architect i2000sr, by Abbott (1 mentions)
3 protocols using cobas 8000 analyzer series module e801
1
Quantification of Anti-SARS-CoV-2 Antibodies
2
Serum Biomarker Determination Protocol
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Serum GH levels were determined by Electro Chemiluminescence Immunoassay using Cobas 8000 analyzer series module e801 (Roche Diagnostics, Mannheim, Germany; %CV of intra-assay variability <15%). The serum glucose level was determined by hexokinase enzymatic method (L-type Wako Glu2; Wako Pure Chemical Industries, Osaka, Japan) using LABOSPECT 008 α (HITACHI, Tokyo, Japan) and JCA-BM8060 (JEOL, Tokyo, Japan). The lactate level was determined by enzymatic method (Deteminer LA; Minaris Medical, Tokyo, Japan) using JCA-BM9130 (JEOL, Tokyo, Japan). Serum insulin levels were determined by Chemiluminescent Immunoassay using Architect i2000 SR (Abbott, Osaka, Japan). Plasma amino acids fractionation was determined by High-Pressure Liquid Chromatography using a Modification of the 6-Aminoquinolyl-N-Hydroxysuccinimidyl Carbamate (AQC) Method on a Waters Acquity UPLC system. GH, glucose, insulin, amino acids, and lactate levels were analyzed by the LSI Medience Corporation (Kyoto, Japan). Acylated ghrelin levels were measured using an Active Ghrelin ELISA Kit (# 97751, LSI Medience, Tokyo, Japan).
3
Glucose Metabolism Assessment in Acromegaly
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
All patients with acromegaly underwent the 75-g OGTT, and blood samples for measuring PG and GH levels were collected before and 30, 60, and 120 min after glucose intake. GA and HbA 1c levels were measured in patients with acromegaly or severe AGHD before GH levels were normalized by specific treatments such as resection of a GH-producing adenoma or GH replacement therapy. PG level was measured using the glucose oxidase method (Glucose analyzer GA 08, A&T Corporation, Kanagawa, Japan; percentage coefficient of variation [%CV] of intra-assay variability <0.8%). GA level was measured by enzymatic synthesis using the automated system Lucica TM glycated albumin-L assay kit (Asahi Kasei Pharma, Tokyo, Japan; %CV of intra-assay variability <0.51). HbA 1c levels were expressed as National Glycohemoglobin Standardization Program (NGSP) values and measured by high-performance liquid chromatography using an automated HLC-728G8 system (Tosoh Corp., Tokyo, Japan; %CV of intra-assay variability <0.3%). The reference ranges of HbA 1c and GA are 4.6%-6.2% and 11.0%-16.0%, respectively. Serum GH level was measured by electrochemiluminescence immunoassay using Cobas 8000 analyzer series module e801 (Roche Diagnostics, Mannheim, Germany; %CV of intra-assay variability <15%).
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!